Diffuse Large B-Cell Lymphoma News

News

Tafasitamab Plus R-CHOP With or Without Lenalidomide Yields Encouraging Efficacy, Manageable Safety Among Patients With Untreated DLBCL

11/28/2023

Jordan Kadish

A combination of tafasitamab plus R-CHOP with or without the addition of lenalidomide demonstrated encouraging efficacy and manageable safety among patients with untreated diffuse large B-cell lymphoma, according to study results.

A combination of tafasitamab...

11/28/2023

Oncology

News

BTK Inhibitor Acalabrutinib Plus STAT3 Inhibitor Danvatirsen for R/R DLBCL

11/15/2023

Jordan Kadish

BTK inhibitor acalabrutinib plus STAT3 inhibitor danvatirsen therapy yielded safe and tolerable outcomes among patients with R/R DLBCL, but demonstrated limited efficacy outcomes, according to a phase 1 study.

BTK inhibitor acalabrutinib plus...

11/15/2023

Oncology

News

Comparing Chemotherapy Cycles Using Positron Emission Tomography-Adapted Therapy Among Patients With Non-Bulky, Low-Risk DLBCL

10/24/2023

Jordan Kadish

A 4-cycle regimen of chemotherapy showed comparable efficacy to a 6-cycle regimen for patients with low-risk, non-bulky DLBCL with interim positron emission tomography with computed tomography confirmed complete response, according to a phase...

A 4-cycle regimen of...

10/24/2023

Oncology

News

Mosunetuzumab Monotherapy Yields Notable Efficacy, Manageable Safety for R/R DLBCL, Including for Patients With Prior CAR T-Cell Therapy

09/26/2023

Jordan Kadish

Mosunetuzumab monotherapy demonstrated strong efficacy and a manageable safety profile among patients with relapsed/refractory diffuse large B-cell lymphoma, including those previously treated with CAR T-cell therapy.

Mosunetuzumab monotherapy...

09/26/2023

Oncology

News

Predictive Value of CIRS-Derived Comorbidity Index for Patients With R/R DLBCL Indicated for CAR T-Cell Therapy

08/30/2023

Jordan Kadish

A simplified CIRS-derived comorbidity index predicted outcomes among patients with R/R diffuse large B-cell lymphoma indicated for CAR T-cell therapy, according to a retrospective analysis.

A simplified CIRS-derived...

08/30/2023

Oncology

News

BET Inhibitor Trotabresib Demonstrated Antitumor Activity Among Patients With Heavily Pretreated R/R DLBCL

08/01/2023

Jordan Kadish

Oral BET inhibitor trotabresib showed antitumor activity profile among patients with heavily pretreated R/R diffuse large B-cell lymphoma or advanced solid tumors, demonstrating its potential value in combination with other anticancer agents.

Oral BET inhibitor trotabresib...

08/01/2023

Oncology

News

Upfront High-Dose Chemotherapy Followed by Auto-HSCT Improved Prognosis Among Patients With High-Intermediate/High-Risk Stage IV DLBCL

07/27/2023

Jordan Kadish

Upfront chemotherapy followed by autologous hematopoietic stem-cell transplantation yielded effective results among patients with intermediate/high-risk stage IV DLBCL not otherwise specified, according to a retrospective cohort study.

Upfront chemotherapy followed by...

07/27/2023

Oncology

News

Atezolizumab Plus R-CHOP Therapy Among Patients With Previously Untreated DLBCL

07/25/2023

Jordan Kadish

Atezolizumab plus R-CHOP demonstrated durable clinical efficacy among patients with previously untreated DLBCL, however the benefit compared with a regimen of R-CHOP alone is likely to be insignificant, according to a phase 1b/2 trial.

Atezolizumab plus R-CHOP...

07/25/2023

Oncology

News

Carfilzomib Plus R-ICE Regimen Well-Tolerated Among Patients With Relapsed/Refractory DLBCL

06/26/2023

Jordan Kadish

The addition of carfilzomib to the rituximab, ifosfamide, carboplatin, and etoposide treatment regimen was well-tolerated among patients with R/R DLBCL.

The addition of carfilzomib to...

06/26/2023

Oncology

News

FDA Grants Accelerated Approval to Glofitamab for Patients With R/R Diffuse Large B-Cell Lymphoma

06/23/2023

Jordan Kadish

On June 15, 2023, the FDA granted accelerated approval to glofitamab-gxbm for the treatment of patients with relapsed/refractory DLBCL, not otherwise specified, or large B-cell lymphoma arising from follicular lymphoma after ≥ 2 lines of...

On June 15, 2023, the FDA...

06/23/2023

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology